TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

1.600 -0.110 (-6.42%)

Streaming Delayed Price Updated: 10:32 AM EDT, Sep 29, 2026 Add to My Watchlist

Price and Volume

Volume	4,412
Open	1.730
Bid (Size)	1.600 (100)
Ask (Size)	1.690 (300)
Prev. Close	1.710
Today's Range	1.600 - 1.810
52wk Range	1.579 - 20.99
Shares Outstanding	833,683
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Updated Phase 1a Data for TTX-MC138 in Advanced Solid Tumors

September 28, 2026

Via Investor Brand Network

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Expands Global Patent Portfolio for RNA-Based Cancer Therapies

September 22, 2026

Via Investor Brand Network

Performance

YTD	-78.4%	-78.4%
1 Month	-23.8%	-23.8%
3 Month	-69.5%	-69.5%
6 Month	-81.3%	-81.3%
1 Year	-85.0%	-85.0%

More News

Join Today's Live Investor Webinar with TransCode Therapeutics

September 16, 2026

From RedChip Companies, Inc. (Media Suite)

Via ACCESS Newswire

NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Names John Tattory Interim CFO Following Tom Fitzgerald Retirement

September 11, 2026

Via Investor Brand Network

Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

September 03, 2026

From RedChip Companies, Inc. (Media Suite)

Via ACCESS Newswire

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports TTX-MC138 Survival Benefit in Preclinical Breast Cancer Bone Metastasis Study

August 31, 2026

Via Investor Brand Network

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 07, 2026

From RedChip Companies, Inc. (Media Suite)

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 03, 2026

Via Benzinga

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Host First R&D Webcast Highlighting Phase 2a Oncology Program

June 08, 2026

Via Investor Brand Network

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a

June 03, 2026

Via Investor Brand Network

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease

May 27, 2026

Via Investor Brand Network

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University

April 27, 2026

Via Investor Brand Network

MissionIRNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement

April 07, 2026

Via Investor Brand Network

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates

March 03, 2026

Via Investor Brand Network

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach

February 23, 2026

Via Investor Brand Network

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

February 05, 2026

Via Investor Brand Network

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma

January 06, 2026

Via Investor Brand Network

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors

December 22, 2025

Via Investor Brand Network

The market is filled with gapping stocks in Thursday's session. ↗

December 11, 2025

Via Chartmill

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial

December 11, 2025

Via Investor Brand Network

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer

November 17, 2025

Via Investor Brand Network

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation

October 14, 2025

Via Investor Brand Network

MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside

October 08, 2025

Via AB Newswire

InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138

October 08, 2025

Via Investor Brand Network

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout ↗

October 08, 2025

Via Benzinga

Frequently Asked Questions

Is TransCode Therapeutics, Inc. - Common Stock publicly traded?

Yes, TransCode Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does TransCode Therapeutics, Inc. - Common Stock trade on?

TransCode Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for TransCode Therapeutics, Inc. - Common Stock?

The ticker symbol for TransCode Therapeutics, Inc. - Common Stock is RNAZ on the Nasdaq Stock Market

What is the current price of TransCode Therapeutics, Inc. - Common Stock?

The current price of TransCode Therapeutics, Inc. - Common Stock is 1.600

When was TransCode Therapeutics, Inc. - Common Stock last traded?

The last trade of TransCode Therapeutics, Inc. - Common Stock was at 09/29/26 10:32 AM ET

What is the market capitalization of TransCode Therapeutics, Inc. - Common Stock?

The market capitalization of TransCode Therapeutics, Inc. - Common Stock is 1.33M

How many shares of TransCode Therapeutics, Inc. - Common Stock are outstanding?

TransCode Therapeutics, Inc. - Common Stock has 1M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.